AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3084616 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergokryptine 2, 3, or 4.5 mg
Number of subjects: 32
Study 3084616 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergokryptine 2.5 and 5 mg
Number of subjects: 32
Study 3084616 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergokryptine
Number of subjects: 32
Study 3084616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 3084616 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 300 mg iv
Number of subjects: 32
Study 3084616 — intervention group
Group type: COMPARATOR
Intervention: Sulpiride 10 mg im
Number of subjects: 32
Study 3084616 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine 2.5 mg
Number of subjects: 32
Study 31842048 — intervention group
Group type: EXPERIMENTAL
Intervention: RANDOM (randomized testing order)
Number of subjects: 50
Study 30043066 — intervention group
Group type: EXPERIMENTAL
Intervention: Early in-bed leg cycling plus electrical stimulation of the quadriceps muscles added to standardized early rehabilitation (n=159)
Number of subjects: 314
Study 30043066 — intervention group
Group type: COMPARATOR
Intervention: Standardized early rehabilitation alone (usual care) (n=155)
Number of subjects: 314
Study 27496662 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Endobutton device (group A)
Number of subjects: 80
Study 27496662 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple Endobutton device (group B)
Number of subjects: 80
Study 25715902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided pulsed radiofrequency treatment (UG-PRF)
Number of subjects: 100
Study 25715902 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 100
Study 23314413 — intervention group
Group type: EXPERIMENTAL
Intervention: Mogen clamp
Number of subjects: 302
Study 23314413 — intervention group
Group type: COMPARATOR
Intervention: Plastibell
Number of subjects: 302
Study 22945782 — intervention group
Group type: EXPERIMENTAL
Intervention: Salacia chinensis 1000 mg twice-daily
Number of subjects: 30
Study 22945782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22945782 — intervention group
Group type: EXPERIMENTAL
Intervention: Salacia chinensis
Number of subjects: 30
Study 17917819 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Training (PT, n=71)
Number of subjects: 147
Study 17917819 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Training plus Cognitive-Behavioural Training (PT+CBT, n=76)
Number of subjects: 147
Study 17917819 — intervention group
Group type: COMPARATOR
Intervention: Control Group (not explicitly mentioned)
Number of subjects: 147
Study 18650577 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified (single puncture) ilioinguinal and iliohypogastric nerve block with 0.1 ml/kg of 0.25% bupivacaine (Group I)
Number of subjects: 60
Study 18650577 — intervention group
Group type: COMPARATOR
Intervention: Caudal block with 1 ml/kg of 0.25% bupivacaine (Group II)
Number of subjects: 60
Study 12547466 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 536
Study 12547466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 536
Study 10631196 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute pulmonary embolism (PE) patients with no other source of fever
Number of subjects: 311
Study 10631196 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute pulmonary embolism (PE) patients with pulmonary hemorrhage or infarction
Number of subjects: 311
Study 10631196 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute pulmonary embolism (PE) patients without pulmonary hemorrhage or infarction
Number of subjects: 311
Study 8765628 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at a dose of 20 to 40 ppm, advanced to 80 ppm if PaO2 remained less than 100 mm Hg (13.3 kPa)
Number of subjects: 17
Study 8765628 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment without NO)
Number of subjects: 17
Study 1608408 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program in geriatric psychopharmacology (experimental nursing homes)
Number of subjects: 823
Study 1608408 — intervention group
Group type: COMPARATOR
Intervention: Control nursing homes
Number of subjects: 823
Study 1608408 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 823
Study 2865422 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketoconazole
Number of subjects: 0
Study 2865422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30285507 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine (GON and SON blockade)
Number of subjects: 87
Study 30285507 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 87
Study 30049885 — intervention group
Group type: EXPERIMENTAL
Intervention: CapOX plus bevacizumab (CapOX/BEV arm: bevacizumab 7.5 mg/kg and oxaliplatin 130 mg/m2 on day 1 and oral capecitabine 2,000 mg/m2 on days 1‐14, every 3 weeks)
Number of subjects: 107
Study 30049885 — intervention group
Group type: EXPERIMENTAL
Intervention: CapIRI plus bevacizumab (CapIRI/BEV arm: bevacizumab 7.5 mg/kg and irinotecan 200 mg/m2 on day 1 and capecitabine 1,600 mg/m2 on days 1‐14, every 3 weeks)
Number of subjects: 107
Study 27623721 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg tramadol (Group T0.5)
Number of subjects: 144
Study 27623721 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg tramadol (Group T0.25)
Number of subjects: 144
Study 27623721 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 0.05 ml/kg (Group TNS)
Number of subjects: 144
Study 25141016 — intervention group
Group type: EXPERIMENTAL
Intervention: Papacárie®
Number of subjects: 46
Study 25141016 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisolv™
Number of subjects: 46
Study 25141016 — intervention group
Group type: COMPARATOR
Intervention: Manual (excavators)
Number of subjects: 46
Study 23068783 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Analgesia (PCA)
Number of subjects: 0
Study 23068783 — intervention group
Group type: COMPARATOR
Intervention: Boluses of analgesia (control)
Number of subjects: 0
Study 20945260 — intervention group
Group type: EXPERIMENTAL
Intervention: PolyHeme®
Number of subjects: 0
Study 20945260 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 20945260 — intervention group
Group type: COMPARATOR
Intervention: Blood
Number of subjects: 0
Study 18852400 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay-for-performance program offering $5000 for 50 quitline referrals
Number of subjects: 49
Study 18852400 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 49
Study 18852400 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay-for-performance program
Number of subjects: 49
Study 15670982 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g/day sc-FOS for 5 weeks
Number of subjects: 11
Study 15670982 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 weeks
Number of subjects: 11
Study 11865814 — intervention group
Group type: EXPERIMENTAL
Intervention: TMTX 110 mg/m2 followed 24 h later by LV 200 mg/m2/5-FU 500 mg/m2 plus oral LV rescue, given weekly for 6 weeks every 8 weeks.
Number of subjects: 365
Study 11865814 — intervention group
Group type: COMPARATOR
Intervention: 5-FU 600 mg/m2 with LV 200 mg/m2, given weekly for 6 weeks every 8 weeks.
Number of subjects: 365
Study 11865814 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms (TMTX/5-FU/LV and 5-FU/LV)
Number of subjects: 365
Study 10836659 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone 2 mg/30 microg ethinylestradiol
Number of subjects: 100
Study 10836659 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone 3 mg/30 microg ethinylestradiol
Number of subjects: 100
Study 10836659 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone alone (2 mg and 3 mg)
Number of subjects: 100
Study 10836659 — intervention group
Group type: COMPARATOR
Intervention: Drospirenone alone (0.5 mg, 1.0 mg, 2.0 mg, 3.0 mg)
Number of subjects: 100
Study 9586530 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush (Rowenta)
Number of subjects: 73
Study 9586530 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (Elmex)
Number of subjects: 73
Study 8145175 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 181
Study 8145175 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 181
Study 8145175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 2431648 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine (30 ml) diluted with 0.9% saline
Number of subjects: 50
Study 2431648 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (30 ml) diluted with dextran 110
Number of subjects: 50
Study 30004828 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on health beliefs model (HBM)
Number of subjects: 70
Study 30004828 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 70
Study 26993105 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin nasal spray 200 IU/day once a day for 3 months after surgery
Number of subjects: 24
Study 26993105 — intervention group
Group type: COMPARATOR
Intervention: Placebo once a day for 3 months after surgery
Number of subjects: 24
Study 24884585 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (250 mg daily)
Number of subjects: 0
Study 24884585 — intervention group
Group type: COMPARATOR
Intervention: Placebo (250 mg of olive oil daily)
Number of subjects: 0
Study 23136909 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01
Number of subjects: 6537
Study 23136909 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparator vaccine)
Number of subjects: 6537
Study 21029821 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/20 mg
Number of subjects: 1289
Study 21029821 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/40 mg
Number of subjects: 1289
Study 21029821 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 10 mg
Number of subjects: 1289
Study 21029821 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 20 mg
Number of subjects: 1289
Study 21029821 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 40 mg
Number of subjects: 1289
Study 21029821 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin
Number of subjects: 1289
Study 18541203 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous HSCT
Number of subjects: 32
Study 18541203 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT
Number of subjects: 32
Study 15996060 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy with adalimumab (7 infusions: Week 0, 2, 4, 6, 8, 10, and 12)
Number of subjects: 13
Study 15996060 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy with adalimumab
Number of subjects: 13
Study 15996060 — intervention group
Group type: COMPARATOR
Intervention: Baseline levels of sex hormones in patients with RA
Number of subjects: 13
Study 12085316 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline qualitative plasma CMV polymerase chain reaction (PCR) positivity
Number of subjects: 378
Study 12085316 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-updated PCR positivity
Number of subjects: 378
Study 12085316 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in cumulative PCR status
Number of subjects: 378
Study 10476893 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus tetracycline fibers
Number of subjects: 30
Study 10476893 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing only
Number of subjects: 30
Study 8942411 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-fortified formula
Number of subjects: 3
Study 8942411 — intervention group
Group type: COMPARATOR
Intervention: Cholesterol-unfortified formula
Number of subjects: 3
Study 8942411 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed
Number of subjects: 3
Study 2013505 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin with metronidazole
Number of subjects: 80
Study 2013505 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid with metronidazole
Number of subjects: 80
Study 30947727 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-ocean mineral water
Number of subjects: 17
Study 30947727 — intervention group
Group type: COMPARATOR
Intervention: Mountain spring water
Number of subjects: 17
Study 30947727 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-based sports drink
Number of subjects: 17
Study 28598899 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine ER 75-225 mg/day
Number of subjects: 0
Study 28598899 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 25462210 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (600 μg/24 hours by infusion)
Number of subjects: 87
Study 25462210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 23458319 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered transdiagnostic cognitive behavioural therapy (iCBT)
Number of subjects: 129
Study 21411655 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg naloxone
Number of subjects: 0
Study 19438775 — intervention group
Group type: EXPERIMENTAL
Intervention: Pump flow rate calculated on ideal BMI of 25
Number of subjects: 0
Study 19438775 — intervention group
Group type: COMPARATOR
Intervention: Traditional pump flow rate set on 2.4 L/min/m(2) of body surface area
Number of subjects: 0
Study 17605563 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation
Number of subjects: 87
Study 17605563 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 87
Study 15008675 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonverbal serial-order task training
Number of subjects: 5
Study 11480809 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine and 1% thymol varnish
Number of subjects: 25
Study 11480809 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 25
Study 9570197 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine hydrochloride 1 mg/min
Number of subjects: 20
Study 9570197 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study 7978099 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.25 mg bid
Number of subjects: 71
Study 7978099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 2558365 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurokinin A (0.02 ml, 10(‐5)M)
Number of subjects: 6
Study 2558365 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6
Study 1201769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fat solution containing 40 g of soy bean oil
Number of subjects: 35
Study 1201769 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fat solution containing 40 g of soy bean oil
Number of subjects: 35
Study 1201769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal fat solution containing 40 g of soy bean oil
Number of subjects: 35
Study 1201769 — intervention group
Group type: COMPARATOR
Intervention: Intravenous, oral, and intraduodenal fat administration
Number of subjects: 35
Study 30084112 — intervention group
Group type: EXPERIMENTAL
Intervention: GEMI/ROSU FDC (gemigliptin 50 mg and rosuvastatin 20 mg)
Number of subjects: 290
Study 30084112 — intervention group
Group type: COMPARATOR
Intervention: GEMI (gemigliptin 50 mg)
Number of subjects: 290
Study 30084112 — intervention group
Group type: COMPARATOR
Intervention: ROSU (rosuvastatin 20 mg)
Number of subjects: 290
Study 30084112 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 290
Study 28608666 — intervention group
Group type: EXPERIMENTAL
Intervention: Kistinox® Forte, 1 sachet per day during the first 10 days of the month for 3 months
Number of subjects: 150
Study 28608666 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 150
Study 25343689 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders (12 messages over 4 weeks, 1 message for 8 weeks thereafter)
Number of subjects: 50
Study 25343689 — intervention group
Group type: COMPARATOR
Intervention: Control group (no text message reminders)
Number of subjects: 50
Study 23518286 — intervention group
Group type: EXPERIMENTAL
Intervention: HF rTMS (20 Hz, 10 Hz, sham)
Number of subjects: 66
Study 20566267 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-point scale with descriptors for all scale points
Number of subjects: 1000
Study 20566267 — intervention group
Group type: COMPARATOR
Intervention: 10-point scale with descriptors only at the end points
Number of subjects: 1000
Study 19107051 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg of dexamethasone administered intravitreally
Number of subjects: 0
Study 19107051 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids and antibiotics (general reference)
Number of subjects: 0
Study 16418097 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-intervention group (16-hour workshop)
Number of subjects: 83
Study 16418097 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-intervention group (2-hour class)
Number of subjects: 83
Study 16418097 — intervention group
Group type: COMPARATOR
Intervention: Control group (toxicology program)
Number of subjects: 83
Study 12919154 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.02 mg/kg orally at -90 min)
Number of subjects: 8
Study 12919154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 11887256 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to psychiatric nursing theory and practice (experimental group)
Number of subjects: 0
Study 11887256 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exposure to psychiatric nursing theory and practice)
Number of subjects: 0
Study 8740084 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuaminoheptane/N-acetyl-cysteine (THS/NAC)
Number of subjects: 18
Study 8740084 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylometazoline
Number of subjects: 18
Study 8740084 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 18
Study 1342906 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 0.1% solution
Number of subjects: 40
Study 1342906 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 1% solution
Number of subjects: 40
Study 1342906 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 0.5% solution
Number of subjects: 40
Study 1342906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 4058820 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Tucker‐McLane forceps
Number of subjects: 118
Study 4058820 — intervention group
Group type: EXPERIMENTAL
Intervention: Silastic vacuum extraction system
Number of subjects: 118
Study 4058820 — intervention group
Group type: EXPERIMENTAL
Intervention: Mityvac vacuum extractor
Number of subjects: 118
Study 27940899 — intervention group
Group type: EXPERIMENTAL
Intervention: In-depth recommendations by the physician reinforced with SMS messages (Group 2)
Number of subjects: 40
Study 27940899 — intervention group
Group type: COMPARATOR
Intervention: Minimal recommendations by the physician (Group 1)
Number of subjects: 40
Study 25941207 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention in grade 6 and school-based drug preventive intervention in grade 7
Number of subjects: 424
Study 25941207 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 424
Study 25941207 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention and school-based drug preventive intervention
Number of subjects: 424
Study 25027229 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (feedback information programs directed to GPs)
Number of subjects: 0
Study 25027229 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 25027229 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0
Study 22694350 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri-containing tablets
Number of subjects: 40
Study 20228677 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (16 mmol bolus, 8 mmol/hr infusion for 10 days)
Number of subjects: 110
Study 18771581 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger Trainer (20 min every work day for four weeks)
Number of subjects: 10
Study 18771581 — intervention group
Group type: COMPARATOR
Intervention: Bimanual group therapy (20 min every work day for four weeks)
Number of subjects: 10
Study 15924667 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + Radiotherapy (C + R group)
Number of subjects: 186
Study 15924667 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (R group)
Number of subjects: 186
Study 14676046 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine 13.5 mg
Number of subjects: 242
Study 14676046 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine 18.0 mg
Number of subjects: 242
Study 14676046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 11014414 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose LY293558 (1.2 mg/kg)
Number of subjects: 70
Study 11014414 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine (30 mg)
Number of subjects: 70
Study 11014414 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose LY293558 (0.4 mg/kg)
Number of subjects: 70
Study 11014414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 9006245 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education materials written at a lower reading level (3rd-grade level)
Number of subjects: 252
Study 9006245 — intervention group
Group type: COMPARATOR
Intervention: Health education materials written at a higher reading level (10th-grade level)
Number of subjects: 252
Study 1620773 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking therapy
Number of subjects: 37